Sage Journals: Discover world-class research

Abstract

Background

Metabolic syndrome (MetS) is associated with increased risk for cardiovascular disease, but there is heterogeneity in this risk. We evaluated whether high-sensitivity troponin T (hs-cTnT), a marker associated with cardiovascular disease, can stratify risk in MetS.

Methods

We evaluated associations between MetS (and groups with similar number of MetS components) and incident heart failure hospitalization, coronary heart disease, stroke and death using hs-cTnT categories after adjusting for risk factors/markers between 1996 and 2011 in 8204 individuals in the Atherosclerosis Risk In Communities study.

Results

The mean age of the population was 63 years (56% women, 19% Blacks). hs-cTnT levels were higher with MetS and with increasing MetS components. In individuals with MetS, higher hs-cTnT levels were associated with increased hazard ratios for heart failure, coronary heart disease and death. Within each number of MetS components, higher hs-cTnT was associated with progressively higher heart failure, coronary heart disease and death hazards. The association was particularly strong for heart failure. With increasing hs-cTnT categories, the hazard ratios (95% confidence interval) for heart failure in individuals with MetS increased gradually from 1.68 (1.31–2.16) to 3.76 (2.69–5.26) (p-trend < 0.001) compared with those with MetS and hs-cTnT < 5 ng/l; and respective hazard ratios with increasing hs-cTnT categories in those with all five MetS components ranged from 2.22 (1.17–4.21) to 4.23 (1.89–9.50) (p-trend 0.004) compared with those with all five MetS components and hs-cTnT < 5 ng/l. However, mostly there were no significant interactions of hs-cTnT with MetS or its components.

Conclusion

hs-cTnT is useful for identifying MetS patients with increased hazards for coronary heart disease, death and particularly heart failure.

Keywords

Metabolic syndrome high-sensitive troponin T risk stratification heart failure coronary heart disease

Get full access to this article

View all access options for this article.

References

Grundy

Brewer

Jr Cleeman

. Definition of metabolic syndrome: Report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition. Circulation 2004; 109: 433–438.

Gami

Witt

Howard

. Metabolic syndrome and risk of incident cardiovascular events and death: A systematic review and meta-analysis of longitudinal studies. J Am Coll Cardiol 2007; 49: 403–414.

Hunt

. ACC/AHA 2005 guideline update for the diagnosis and management of chronic heart failure in the adult: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure). J Am Coll Cardiol 2005; 46: e1–e82.

Hunt

Abraham

Chin

. 2009 Focused update incorporated into the ACC/AHA 2005 Guidelines for the diagnosis and management of heart failure in adults. A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines developed in collaboration with the International Society for Heart and Lung Transplantation. J Am Coll Cardiol 2009; 53: e1–e90.

Mozaffarian

Kamineni

Prineas

. Metabolic syndrome and mortality in older adults: The Cardiovascular Health Study. Arch Intern Med 2008; 168: 969–978.

Reichlin

Hochholzer

Bassetti

. Early diagnosis of myocardial infarction with sensitive cardiac troponin assays. N Engl J Med 2009; 361: 858–867.

de Lemos

Drazner

Omland

. Association of troponin T detected with a highly sensitive assay and cardiac structure and mortality risk in the general population. JAMA 2010; 304: 2503–2512.

deFilippi

de Lemos

Christenson

. Association of serial measures of cardiac troponin T using a sensitive assay with incident heart failure and cardiovascular mortality in older adults. JAMA 2010; 304: 2494–2502.

Saunders

Nambi

de Lemos

. Cardiac troponin T measured by a highly sensitive assay predicts coronary heart disease, heart failure, and mortality in the Atherosclerosis Risk in Communities Study. Circulation 2011; 123: 1367–1376.

10.

Pokharel

Sun

de Lemos

. High-sensitivity troponin T and cardiovascular events in systolic blood pressure categories: Atherosclerosis Risk in Communities study. Hypertension 2015; 65: 78–84.

11.

The Atherosclerosis Risk in Communities (ARIC) Study: Design and objectives. The ARIC investigators. Am J Epidemiol 1989; 129: 687–702.

12.

The National Heart, Lung, and Blood Institute of the National Institutes of Health. Atherosclerosis Risk in Communities Study protocol: Manual 11: Sitting blood pressure: Visit 4. Version 4.0 ed. Chapel Hill, NC: ARIC Coordinating Center, 1997.

13.

The National Heart, Lung, and Blood Institute of the National Institutes of Health. Atherosclerosis Risk in Communities Study: Manual 8: Lipid and lipoprotein determinations. Version 2.0 ed. Chapel Hill, NC: ARIC Coordinating Center, 1994.

14.

Levey

Stevens

Schmid

. A new equation to estimate glomerular filtration rate. Ann Intern Med 2009; 150: 604–612.

15.

Atherosclerosis Risk In Communities (ARIC) Study: Anthropometry Form 1998. https://www2.cscc.unc.edu/aric/sites/default/files/public/forms/ANTD.pdf (accessed 29 October 2015).

16.

White

Folsom

Chambless

. Community surveillance of coronary heart disease in the Atherosclerosis Risk in Communities (ARIC) Study: Methods and initial two years’ experience. J Clin Epidemiol 1996; 49: 223–233.

17.

Rathore

Hinn

Cooper

. Characterization of incident stroke signs and symptoms: Findings from the Atherosclerosis Risk in Communities study. Stroke 2002; 33: 2718–2721.

18.

Rosamond

Chang

Baggett

. Classification of heart failure in the atherosclerosis risk in communities (ARIC) study: A comparison of diagnostic criteria. Circ Heart Fail 2012; 5: 152–159.

19.

Witteles

Fowler

. Insulin-resistant cardiomyopathy clinical evidence, mechanisms, and treatment options. J Am Coll Cardiol 2008; 51: 93–102.

20.

Scuteri

Laurent

Cucca

. Metabolic syndrome across Europe: Different clusters of risk factors. Eur J Prev Cardiol 2015; 22: 486–491.

21.

Ridker

Buring

Cook

. C-reactive protein, the metabolic syndrome, and risk of incident cardiovascular events: An 8-year follow-up of 14 719 initially healthy American women. Circulation 2003; 107: 391–397.

22.

Pervanidou

Akalestos

Bastaki

. Increased circulating high-sensitivity troponin T concentrations in children and adolescents with obesity and the metabolic syndrome: A marker for early cardiac damage? Metabolism: Clinical and Experimental 2013; 62: 527–531.

23.

Zeng

Dong

Wang

. Obesity and novel cardiovascular markers in a population without diabetes and cardiovascular disease in China. Prev Med 2016; 91: 62–69.

24.

Selvin

Lazo

Chen

. Diabetes mellitus, prediabetes, and incidence of subclinical myocardial damage. Circulation 2014; 130: 1374–1382.

25.

Zinman

Wanner

Lachin

. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 2015; 373: 2117–2128.

Supplementary Material

Please find the following supplemental material available below.

For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.

For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.

0.00 MB

2.73 MB

Association between high-sensitivity troponin T and cardiovascular risk in individuals with and without metabolic syndrome: The ARIC study

Abstract

Background

Methods

Results

Conclusion

Keywords

Get full access to this article

References

Supplementary Material